Resultados de la búsqueda 371-380 of 14663 for Severe hypertriglyceridaemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...
The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events at 2 years of follow up ...
Heart, Lung & Circulation. 2019; doi:10.1016/j.hlc.2018.09.005. Podrid PJ, et al. Ventricular arrhythmias during acute myocardial infarction: Incidence, ...
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore ...
A total of 8,000 patients presenting to CPSs with acute-onset AIS, ICH or aSAH and no history of dementia will be enrolled within 6 weeks of stroke onset. All ...
... Chronic Lymphocytic Leukemia. Rochester, Minn. This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab ...
... acute kidney injury provides strong predictive ability for AKI and potential therapeutic targets. ... acute kidney injury provides strong predictive ...
... severe residual upper-extremity motor impairment due to stroke. A Study To Create A Registry Of Non-Fusion Spinal Deformity Correction In Adolescent ...
... acute ischemic stroke or high risk TIA (1) reduces recurrent stroke, acute coronary syndrome, and all-cause mortality 6 months after the event, and (2) ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?